SPINA, Edoardo
 Distribuzione geografica
Continente #
NA - Nord America 8.331
EU - Europa 7.128
AS - Asia 1.149
OC - Oceania 12
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 6
Totale 16.645
Nazione #
US - Stati Uniti d'America 8.297
IE - Irlanda 2.082
SE - Svezia 1.676
CN - Cina 1.050
UA - Ucraina 861
IT - Italia 860
DE - Germania 643
FI - Finlandia 370
GB - Regno Unito 236
PL - Polonia 158
FR - Francia 83
BE - Belgio 52
IN - India 50
RU - Federazione Russa 35
NL - Olanda 31
CA - Canada 29
VN - Vietnam 18
TR - Turchia 11
AU - Australia 10
CL - Cile 9
CH - Svizzera 7
AT - Austria 6
ES - Italia 6
EU - Europa 6
IR - Iran 5
MX - Messico 5
AL - Albania 4
RO - Romania 4
CZ - Repubblica Ceca 3
IL - Israele 3
JP - Giappone 3
A1 - Anonimo 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
HK - Hong Kong 2
ID - Indonesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BR - Brasile 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LT - Lituania 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 16.645
Città #
Dublin 2.079
Jacksonville 1.747
Chandler 1.522
Nyköping 751
Beijing 516
Ashburn 409
Princeton 400
Cambridge 361
Dearborn 358
Des Moines 277
Medford 247
Boardman 210
Ann Arbor 194
Messina 172
Warsaw 156
Wilmington 123
New York 110
Lancaster 93
Houston 84
Woodbridge 77
Jinan 74
Seattle 65
San Mateo 64
Shenyang 64
Bremen 62
Brussels 52
Nanjing 47
Milan 46
Pune 43
Hebei 34
Haikou 32
Hangzhou 32
Norwalk 29
Tianjin 29
Ningbo 26
Taizhou 26
Zhengzhou 26
Rome 23
Washington 20
Catania 19
Dong Ket 18
Ottawa 18
Guangzhou 17
Helsinki 17
Changsha 16
Nanchang 16
Fuzhou 15
Jiaxing 15
Saint Petersburg 14
Falls Church 12
Auburn Hills 10
Taiyuan 10
Clearwater 9
Paternò 9
Kastamonu 8
Palermo 8
Tappahannock 8
Verona 8
Bologna 7
Fiumefreddo Di Sicilia 7
Strasbourg 7
Urbino 7
Bari 6
Lanzhou 6
Los Angeles 6
Paris 6
Sarno 6
Torino 6
Vienna 6
Fairfield 5
Florence 5
Genova 5
Naples 5
Napoli 5
Perugia 5
Redmond 5
Riva 5
Salerno 5
Augusta 4
Cefalù 4
Enschede 4
Hanover 4
Mascali 4
Massa 4
Novokuznetsk 4
Philadelphia 4
Redwood City 4
Sesto San Giovanni 4
Sydney 4
Xiangfen 4
Zurich 4
Ardabil 3
Bergamo 3
Brno 3
Caltagirone 3
Cusano Milanino 3
Edinburgh 3
Foggia 3
Hefei 3
London 3
Totale 11.121
Nome #
Cutis verticis gyrata primitiva o pachidermia verticis gyrata: contributo clinico-istologico 297
Efficacia di un trattamento aggiuntivo con olanzapina nel disturbo ossessivo-compulsivo resistente agli SSRI 196
Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study 116
Adverse Drug Reactions in Hospitalized patients: results of the FORWARD (Facilitation of reporting in hospital Ward) study. 107
Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder 100
Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study 96
Augmentation con Lamotrigina in pazienti con schizofrenia resistente in trattamento con Clozapina 94
Aripiprazolo in bambini con ADHD in comorbidità con Disturbo da Tic 91
Confronto Teofillina-Doxofillina nella risoluzione del broncospasmo 90
Uso dell’Aripiprazolo in bambini con Multiple-complex Developmental Disorder (McDD). 88
A molecular pathway analysis informs the genetic background at risk for schizophrenia. 87
Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report 83
Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients: Results from a 60-days open-label study 82
Interazione farmacocinetica tra mirtazapina e clozapina in pazienti schizofrenici. 81
PATTERN PRESCRITTIVO DI FARMACI ANTIEPILETTICI NELL'ANZIANO: STUDIO DI POPOLAZIONE IN UN'AREA DEL SUD ITALIA NEGLI ANNI 2004-2007 79
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population 74
Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder 74
Antidepressant use in the elderly: The role of pharmacodynamics and pharmacokinetics in drug safety 73
ABCB1 polymorphisms influence steady state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. 72
Aripiprazole in Children with Multiple-complex Developmental Disorder (McDD): a case series. 71
“Newer and older antiepileptic drug in southern Italy: a population based study during the years 2003-2005” 70
Aripiprazole in Children with Multiple-complex Developmental Disorder (McDD): a case series. 70
Acute Cerebellar Ataxia Following Meningococcal Group C Conjugate Vaccination 70
No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population 69
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. XVII Congresso Nazionale della Società Italiana di Neuropsicofarmacologia, Cagliari 22-25 Settembre 2010, p. 47. 69
“Effect of valproic acid on plasma concentrations of olanzapine in patients with psychiatric disorders” 68
Antidepressant effect of hypericum perforatum extract on behaviour and neurogenesis in chronic corticosterone-treated mice. 68
Aripiprazole enhances the antidepressant effect of fluoxetine in mice. 67
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study 67
PARKINSONISMO ED INIBITORI SELETTIVI DEL REUPTAKE DELLA SEROTONINA 66
Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications 66
Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? 66
n-3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell (BAFF) transgenic mice 65
Generic Olanzapine Substitution in Patients with Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching 65
Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics 64
"Valproic acid-amitriptyline interaction in man 64
INFLUENCE OF CYP2C9 POLYMORPHISM IN LUNG CANCER SUSCEPTIBILITY 63
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. 63
Ototoxic adverse drug reactions: A disproportionality analysis using the Italian spontaneous reporting database 63
Impiego clinico del Risperidone in età evolutiva: variazioni farmacocinetiche e cliniche 62
Aripiprazole augmentation of serotinin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study 62
Pharmacokinetic interaction between duloxetine and second-generation antipsychotics in patients with psychotic disorders 62
Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study 62
Pharmacogenomics in Psychiatry 62
Impiego del Risperidone nel disturbo autistico: valutazioni farmacocinetiche e cliniche 61
Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011 61
Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice 60
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone 60
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 60
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olazapine and risperidone I patients with psychotic disorders 60
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 60
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. 60
The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia 59
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity 59
AN ENDOCRINOLOGIC STUDY OF PATIENTS WITH PRIMARY-CUTIS-VERTICIS GYRATA 59
5-HT2A and 5-HT2C receptor polymorphisms and psychotic symptoms in Alzheimer's disease 59
Effetto di un trattamento con risperidone o olanzapina sui livelli serici di prolattina in bambini e adolescenti con patologie psichiatriche. 59
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. 59
Age-related changes in pharmacodynamics: focus on drug acting on cetral nervous and cardiovascular systems 59
Evaluation of putative cytotoxic activity of crude extracts from Onopordum acanthium leaves and Spartium junceum flowers against the U-373 glioblastoma cell line. 59
A pharmacokinetic-pharmacodynamic method for predicting warfarin maintenance dose: preliminary results 58
Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. 58
Safety and tolerability of psychotropic medications in childhood: preliminary data of a pharmacovigilance study 58
Off-label use of second-generation antipsychotics 57
“Augmentation con Duloxetina vs. placebo in un campione di schizofrenici partial responders in trattamento stabilizzato con antipsicotici atipici”. 57
Effect of valpromide on the pharmacokinetics of Carbamazepine-10,11-epoxide 57
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 57
Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs. 57
6-Mer Hyaluronan Oligosaccharides ModulateNeuroinflammation and a-Synuclein Expression inNeuron-Like SH-SY5Y Cells 57
Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents 57
Short-term memory loss associated with rosuvastatin. 56
Aripiprazole enhances the antidepressat effect of fluoxetine in mice. 56
Uso dell’aripiprazolo in bambini con Multiple-complex Developmental Disorder. 56
Systemic cardiorespiratory effects induced by doxofylline 56
Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. 56
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder 55
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia 55
Profilo di tollerabilità degli antipsicotici atipici e degli inibitori selettivi della ricaptazione della serotonina in età evolutiva. 55
ANTITHETIC ACTION OF HYALURONAN 6-MER IN UNDIFFERENTIATED AND DIFFERENTIATED SH-SY5Y CELLS 55
Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study. 55
Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies 55
Metabolic drug interactions with newer antipsychotics: a comparative review. 54
Impiego clinico dell'olanzapina in età evolutiva 54
ADJUNCTIVE FLUOXETINE IN THE TREATMENT OF NEGATIVE SYMPTOMS IN CHRONIC-SCHIZOPHRENIC PATIENTS 54
Prescribing pattern of antiepileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-2007 54
Safety and tolerability of antipsychotic drugs in pediatric patients: data from an ongoing active pharmacovigilance study in Sicily 54
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 53
Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease 52
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 52
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders 52
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study 52
Interactions between antiepileptics and second generation antipsychotics 52
ECG parameters in children and adolescents treated with aripiprazole and risperidone 52
Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database 52
Tolerability of antipsychotics in children and adolescents: a prospective study. 51
PHARMACOKINETIC INTERACTIONS BETWEEN TRICYCLIC ANTIDEPRESSANTS AND OTHER PSYCHOTROPIC-DRUGS IN DEPRESSED-PATIENTS 51
Livelli serici di prolattina in corso di trattamento con risperidone o olanzapina in bambini ed adolescenti con patologie psichiatriche. 51
Evaluation of Tricyclic Antidepressant Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison to a High-Performance Liquid Chromatographic Method 51
A double-blind comparative study of bromperidol versus halperidol in schizophrenic patients 51
Fase prodromica della schizofrenia: prospettive diagnostiche ed opportunità terapeutiche 51
Totale 6.754
Categoria #
all - tutte 59.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.430


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201946 0 0 0 0 0 0 0 0 0 17 15 14
2019/20202.891 452 214 12 192 16 378 365 312 56 314 547 33
2020/20212.408 282 22 545 138 156 299 56 243 56 338 133 140
2021/20222.228 27 225 31 78 50 23 133 114 83 446 293 725
2022/20235.906 509 412 218 480 521 543 52 347 2.554 28 176 66
2023/20241.370 121 246 109 169 168 338 70 102 26 21 0 0
Totale 16.979